TP53 and B-cell chronic lymphocytic leukemia: Therefore, the biological studies to request before starting treatment should be FISH, IGHV, and TP53 mutations, regardless of the patient’s frailty status and age, in line with the recommendations of international CLL guidelines [5,6,16].